21 october 2011 - the arrival of phosphagenics

This day will be looked upon as the turning point for phosphagenics.
The extraordinary $24M cash raise that was heavily oversubscribed has finally put any uncertainty of funds to bed. Not only has the cost of the Oxypatch trials been covered but management have stated that incoming revenues from a number of different sources will now make POH a viable commercial entity by becoming self reliant on raising money.

Today some people decided it was worth selling over 9 million shares at between 16.5-17c, whilst some felt it was worth buying those 9 million shares.

I wonder whether people selling thought about what they were doing.

POH has always had the delivery platform technology to revolutionize the drug delivery industry. Now it has the funds that were needed to complete the trials.
Upon completion the oxypatch could easily demand an upfront payment of $100M-$150M and grab a large chunk of the $3-4b oxycodone industry, earning 10-13% royalties per year. Pain medication patches with TPM will not be limited to Oxycodone.

And you sold at 16.5c

POH are collaborating with the 2nd largest dermatological company in the world to develop an anti-acne product in a global market worth $3billion.
Phosphagenics and the dermatology company will discuss commercial arrangements for the final product upon trial completion, expected 4th quarter 2011.

And you sold at 16.5c

POH are collaborating with a private US dermatological company to develop an anti-psoriasis cream. In vitro studies demonstrated that the new formulation delivered the drug five times more effectively than a formulation not using the company’s technology. It is predicted that the global psoriasis market by 2015 will top $7b.

And you sold at 16.5c

POH are about to launch their own Anti-aging and Anti-Cellulite cosmetics Elixia into SE Asia, after successfully launching both in Australia generating over $1M wholesale sales in a few months. There are plans to eventually go fully global by entering markets in USA and Europe. The anti-cellulite market makes up about $3b of global sales out of an estimated $300 billion global anti-aging market by 2015.

And you sold at 16.5c

POH are collaborating with Novartis Animal Industry to develop the world’s first dermal delivery of Insulin for pets. Many believe this is the stepping stone to re-ignite the human insulin patch project. Insulin global market exceeds $14b with animal insulin making up about $100m-$200m of that.

And you sold at 16.5c

POH are developing an improved version of diclofenac gel. The diclofenac global market exceeds $1b. The leading global product Voltaren earns just under $800m per annum, and POH trials have shown that TPM-delivered diclofenac permeates the skin substantially more effectively than the currently available Voltaren® gel.

And you sold at 16.5c

POH are also developing the diclofenac gel as a treatment for Actinic Keratosis and skin condition that is a pre-cursor to skin cancer. It’s leading generic product Solareze sells $350m in the USA alone. Typically Solaraze and competitor products like Aldara or Efudex are slow working and result in the skin getting red and raw, leading to poor compliance rates. By contrast TPM’s anti-inflammatory properties would allow it to be positioned as a superior product

And you sold at 16.5c

POH are developing a lidocaine product that demonstrated the ability to deliver a significantly greater amount of lidocaine into the localised area of the skin compared to a leading commercial product. Global sales exceeded $1.2 billion and the leading lidocaine product earns $700-$800m per annum

And you sold at 16.5c

POH have partnered with Agriculture company MMA to develop anti-mastitis products, a condition that cost the industry $54B per annum. MMA have access to 3000 stores nationwide and as of Sept 2011, Mastitis Management Australia was in late stage discussions with global players in the Animal Health market in particular in relation to Bovine products.

And you sold at 16.5c

POH recently entered into another agreement with a leading global cosmetic and dermatological company to conduct a human study on a new cosmetic product.

Yes, and you sold at 16.5c


POH continues to collaborate with leading biotechnology company CSL and have formulated a series of products containing CSL actives. These products are now being tested. CSL deal mainly with protein biotherapies and Vaccines.

You’re getting my drift about selling at 16.5c

POH have a number of other ongoing projects including, but not limited to TPM powered hair products, the development of a range of products containing AOD-9604, the already registered Skin Whitening product to be launched in Asia, animal feed supplementation, over 10 high end products currently selling via LMDB is USA department stores, development of vitamin products, and in house development of Retinoic Acid for the treatment of acne, food supplementation and POH always have projects that we are yet to be made aware of.

So yes, have you thought about how you sold at 16.5c,

Because I have,

and I bought at 16.5c